Log in

Relevant bibliographies by topics / Pre-exposure prophylaxy / Journal articles

Journal articles on the topic 'Pre-exposure prophylaxy'

To see the other types of publications on this topic, follow the link: Pre-exposure prophylaxy.

Author: Grafiati

Published: 20 April 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pre-exposure prophylaxy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hull, M., and DHS Tan. "Préparer le terrain pour l’élargissement de l’utilisation de la prophylaxie préexposition contre le VIH au Canada." Relevé des maladies transmissibles au Canada 43, no. 12 (December 7, 2017): 310–17. http://dx.doi.org/10.14745/ccdr.v43i12a05f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jesus, Déberson Ferreira de, Glória Luiza Silveira da Silva, and Neuza Cristina Gomes da Costa. "PERCEPÇÃO DE PSICÓLOGOS SOBRE A PROFILAXIA PRÉ-EXPOSIÇÃO AO HIV (PREP) EM MATO GROSSO." Psicologia e Saúde em Debate 9, no. 2 (September 15, 2023): 336–54. http://dx.doi.org/10.22289/2446-922x.v9n2a19.

Full text

Abstract:

HIV Pre-Exposure Prophylaxis (PrEP) is a public health strategy to reduce the probability of HIV acquisition by people at high risk of exposure. This paper addresses the perception of psychologists in the primary health care public system about the PrEP policy in the state of Mato Grosso, Brazil. Through semi-structured interviews, we sought to understand the therapeutic itinerary in the unit where it takes, as well as the opinions and involvement of the psychologists in the implementation of PrEP. There is a lack of definition regarding the attributions and scope of action of the psychologist in relation to PrEP in health units. In some, reception is mandatory in the first service, in others only if there is a request from the user. The interviews revealed that there are distrust and prejudice in relation to the policy and users' social behaviour, as well as the recognition of the lack of training and dissemination as the primary motivations for the low adherence. Psychologists proved to be important professionals in implementing PrEP. Notwithstanding, more dialogue is needed with management at the local and state level so that doubts, beliefs, and social representations are discussed and do not compromise the effectiveness of the policy.

APA, Harvard, Vancouver, ISO, and other styles

3

Popovic, Nashira, Qiuying Yang, and Chris Archibald. "Tendances d’utilisation de la prophylaxie pré-exposition pour le VIH dans huit provinces canadiennes, 2014 à 2018." Relevé des maladies transmissibles au Canada 47, no. 56 (June 9, 2021): 275–83. http://dx.doi.org/10.14745/ccdr.v47i56a02f.

Full text

Abstract:

Contexte : Le Canada a approuvé les objectifs mondiaux du Programme commun des Nations Unies sur le VIH et le Sida visant à mettre fin à l’épidémie du syndrome d’immunodéficience acquise (sida), notamment en réduisant à zéro les nouvelles infections par le virus de l’immunodéficience humaine (VIH) d’ici à 2030. Compte tenu de l’efficacité de la prophylaxie pré-exposition (PPrE) pour prévenir les nouvelles infections, il est important de mesurer et de rendre compte de l’utilisation de la PPrE afin de contribuer à la planification des programmes et des politiques de prévention du VIH. Méthodes : Les estimations annuelles des personnes utilisant de la PPrE au Canada ont été générées pour la période de 2014 à 2018 à partir de l’ensemble de données géographiques de surveillance des ordonnances d’IQVIA. On a utilisé un algorithme pour distinguer les utilisateurs de fumarate de ténofovir disoproxil/emtricitabine (TDF/FTC) pour la PPrE de ceux qui l’utilisent dans le cadre d’un traitement ou de la prophylaxie post-exposition. Nous fournissons le nombre estimé de personnes qui utilisent la PPrE dans huit provinces canadiennes par sexe, groupe d’âge, spécialité du médecin prescripteur et type de paiement. Résultats : Le nombre estimé d’utilisateurs de PPrE a augmenté de façon spectaculaire au cours de la période d’étude de cinq ans : il est multiplié par 21, passant de 460 en 2014 à 9 657 en 2018. La prévalence estimée de la PPrE était de 416 utilisateurs par million de personnes dans les huit provinces en 2018. Presque tous les utilisateurs de PPrE étaient des hommes. L’utilisation a augmenté chez les deux sexes, mais l’augmentation a été plus importante chez les hommes (par 23 fois) que chez les femmes (par 5 fois). L’utilisation a augmenté dans toutes les provinces, bien qu’il y ait des différences entre les provinces relativement à la prévalence de l’utilisation, à la répartition par âge et aux types de médecins prescripteurs. Conclusion : L’utilisation de la PPrE au Canada a augmenté entre 2014 et 2018, ce qui témoigne d’une meilleure connaissance et d’une plus grande adhésion à son utilisation pour prévenir la transmission du VIH. Elle est toutefois inégale en fonction de l’âge, du sexe et de la géographie. Puisque les nouvelles infections au VIH continuent de se produire au Canada, il sera important d’affiner l’utilisation de la PPrE, car les populations à risque plus élevé d’infection au VIH doivent se voir offrir la PPrE dans le cadre de soins de santé sexuelle complets.

APA, Harvard, Vancouver, ISO, and other styles

4

Shewale, Ajit. "A Case for Pre-Exposure Prophylaxis of High-Risk Groups against Rabies in India." Journal of Communicable Diseases 53, no. 01 (March 31, 2021): 110–16. http://dx.doi.org/10.24321/0019.5138.202118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ng, Yeow Chye, and Jack J. Mayeux. "Initiating pre-exposure prophylaxis." Nurse Practitioner 46, no. 8 (August 2021): 17–22. http://dx.doi.org/10.1097/01.npr.0000757076.21006.50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Singh, AjaiKumar, Ashish Singh, Deepti Singh, Manish Singh, Pratibha Singh, and Abhishek Sharma. "HIV: Pre-exposure prophylaxis." International Journal of Preventive Medicine 3, no. 12 (2012): 900. http://dx.doi.org/10.4103/2008-7802.104864.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Morin, S. F., G. Yamey, and G. W. Rutherford. "HIV pre-exposure prophylaxis." BMJ 345, aug13 1 (August 13, 2012): e5412-e5412. http://dx.doi.org/10.1136/bmj.e5412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sharma, Malika, and Darrell H. S. Tan. "HIV pre-exposure prophylaxis." Canadian Medical Association Journal 186, no. 15 (August 5, 2014): E588. http://dx.doi.org/10.1503/cmaj.140127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wille, Lexie, and Mike C. Parent. "Online Prescriptions to HIV Pre-Exposure Prophylaxis and Pre-Exposure Prophylaxis Uptake." AIDS Patient Care and STDs 34, no. 12 (December 1, 2020): 499–501. http://dx.doi.org/10.1089/apc.2020.0196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Atim, M., N. Girometti, I. Hyndman, A. McOwan, G. Whitlock, Keerti Gedela, Sheena McCormack, et al. "Post‐exposure prophylaxis in the era of pre‐exposure prophylaxis." HIV Medicine 21, no. 10 (September 9, 2020): 668–70. http://dx.doi.org/10.1111/hiv.12917.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Marfatia, YS, and Smriti Naswa. "Pre-exposure prophylaxis of HIV." Indian Journal of Sexually Transmitted Diseases and AIDS 32, no. 1 (2011): 1. http://dx.doi.org/10.4103/0253-7184.81246.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Portman, Mags. "Pre-exposure prophylaxis: making history." Sexually Transmitted Infections 93, no. 1 (January 18, 2017): 7. http://dx.doi.org/10.1136/sextrans-2016-053059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Rohan, Lisa C., Haitao Yang, and Lin Wang. "Rectal pre-exposure prophylaxis (PrEP)." Antiviral Research 100 (December 2013): S17—S24. http://dx.doi.org/10.1016/j.antiviral.2013.09.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Trent-Adams, Sylvia, and Laura W. Cheever. "Providing HIV Pre-Exposure Prophylaxis." American Journal of Preventive Medicine 44, no. 1 (January 2013): S147—S150. http://dx.doi.org/10.1016/j.amepre.2012.09.031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Katz, Mitchell H. "Pre-Exposure Prophylaxis for HIV." American Journal of Preventive Medicine 44, no. 1 (January 2013): S161—S162. http://dx.doi.org/10.1016/j.amepre.2012.10.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Curran, James W., and Richard A. Crosby. "Pre-Exposure Prophylaxis for HIV." American Journal of Preventive Medicine 44, no. 1 (January 2013): S163—S166. http://dx.doi.org/10.1016/j.amepre.2012.10.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Robertson, Deborah. "Prescribing pre-exposure prophylaxis therapy." Journal of Prescribing Practice 6, no. 1 (January 2, 2024): 12–14. http://dx.doi.org/10.12968/jprp.2024.6.1.12.

Full text

Abstract:

Deborah Robertson provides an overview of recently published articles that may be of interest to non-medical prescribers. Should you wish to look at any of the papers in more detail, a full reference is provided

APA, Harvard, Vancouver, ISO, and other styles

18

Vanbaelen, Thibaut, Anke Rotsaert, Bart K. M. Jacobs, Eric Florence, Chris Kenyon, Bea Vuylsteke, Marie Laga, and Reyniers Thijs. "Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium." AIDS Patient Care and STDs 36, no. 4 (April 1, 2022): 159–67. http://dx.doi.org/10.1089/apc.2021.0197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Agada, Simon J,. "Barriers to Uptake of Oral Pre-exposure Prophylaxis for HIV among Adolescents’ Young boys and Girls an Assessment of Cross River North Nigeria." TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH 11, no. 2 (June 30, 2023): 281–90. http://dx.doi.org/10.21522/tijph.2013.11.02.art026.

Full text

Abstract:

Antiretroviral pre-exposure prevention (PrEP) to stop HIV transmission was 1st approved by the USA Food and Drug Administration in 2012. Despite correlations of decreases in new HIV infections being greatest wherever PrE-exposure prophylaxis has been deployed, the uptake of PrE-exposure prophylaxis is insulant, significantly among populations with disproportionate HIV burden. This narrative review seeks to spot individual and general barriers to PrE-exposure prophylaxis usage in African country. A comprehensive search of recent literature uncovered a fancy array of structural, social, clinical, and behavioral barriers, as well as knowledge/awareness of PrE exposure prophylaxis, perception of HIV risk, stigma from care suppliers or family/partners/friends, distrust of care providers/systems, access to school assignment, prices of PrE exposure prophylaxis, and issues around school assignment facet effects/medication interactions. significantly, these barriers might have totally different effects on specific populations in danger. The complete potential of PrE-exposure prophylaxis for HIV interference won't be realized till these problems area unit self-addressed. Ways to realize this goal ought to embody academic interventions, innovative approaches to delivery of HIV care, resource, and DE stigmatization of PrE-exposure prophylaxis and PrE-exposure prophylaxis users. Until then, PrE-exposure prophylaxis `uptake can still be suboptimal, significantly among people who would like it most. Results: Stigma influences uptake of pre-exposure prophylaxis; HIV risk perception does not affect uptake of pre-exposure prophylaxis; and a significant negative relationship between stigma and pre-exposure prophylaxis uptake. Conclusion: This study was conducted to investigate barriers to oral pre-exposure prophylaxis. Significant findings of the study conclude: stigma influences uptake of oral pre-exposure prophylaxis for HIV. Keywords: Acquired immunodeficiency syndromes, Barriers, Adolescents, Human immunodeficiency virus, Human immunodeficiency virus testing, Young Boys, Young Girls, Pre-exposure Prophylaxis.

APA, Harvard, Vancouver, ISO, and other styles

20

Crowley, Des, Walter Cullen, and Patrick O’Donnell. "Pre-exposure prophylaxis and primary care." British Journal of General Practice 70, no. 697 (July 30, 2020): 409–10. http://dx.doi.org/10.3399/bjgp20x712097.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Paxton, Lynn A. "Tenofovir-based HIV pre-exposure prophylaxis." Future Virology 8, no. 12 (December 2013): 1207–18. http://dx.doi.org/10.2217/fvl.13.111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Radix, Asa, and Rona Vail. "Pre-exposure Prophylaxis in LGBT Communities." Primary Care: Clinics in Office Practice 48, no. 2 (June 2021): 299–310. http://dx.doi.org/10.1016/j.pop.2021.02.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Fadul, N. "Pre-Exposure Prophylaxis for HIV Prevention." North Carolina Medical Journal 77, no. 5 (September 1, 2016): 361–62. http://dx.doi.org/10.18043/ncm.77.5.361.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Efremova, O. S., and O. G. Yurin. "Pre-exposure prophylaxis of HIV infection." Infekcionnye bolezni 17, no. 1 (2019): 72–76. http://dx.doi.org/10.20953/1729-9225-2019-1-72-76.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bloch, Mark. "Prescribing pre-exposure prophylaxis for HIV." Australian Prescriber 43, no. 6 (December 1, 2020): 200–203. http://dx.doi.org/10.18773/austprescr.2020.057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Myers, Julie E., Tanya M. Ellman, and Carolyn Westhoff. "Injectable agents for pre-exposure prophylaxis." Current Opinion in HIV and AIDS 10, no. 4 (July 2015): 271–77. http://dx.doi.org/10.1097/coh.0000000000000166.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sheth, Anandi N., Charlotte P. Rolle, and Monica Gandhi. "HIV pre-exposure prophylaxis for women." Journal of Virus Eradication 2, no. 3 (July 2016): 149–55. http://dx.doi.org/10.1016/s2055-6640(20)30458-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Grant, Robert M., and David V. Glidden. "HIV moments and pre-exposure prophylaxis." Lancet 387, no. 10027 (April 2016): 1507–8. http://dx.doi.org/10.1016/s0140-6736(16)30125-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Rooney, James. "A-103 Pre-Exposure Prophylaxis (PrEP)." JAIDS Journal of Acquired Immune Deficiency Syndromes 67 (November 2014): 38. http://dx.doi.org/10.1097/01.qai.0000456055.31977.6b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Rowniak, Stefan, and Carmen Portillo. "Pre-Exposure Prophylaxis: An Ethical Discussion." Journal of the Association of Nurses in AIDS Care 24, no. 1 (January 2013): 6–10. http://dx.doi.org/10.1016/j.jana.2012.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Wright, Cameron. "Update on HIV pre-exposure prophylaxis." Journal of Pharmacy Practice and Research 45, no. 1 (March 2015): 124. http://dx.doi.org/10.1002/jppr.1073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Cohen, Stephanie E., Albert Y. Liu, Kyle T. Bernstein, and Susan Philip. "Preparing for HIV Pre-Exposure Prophylaxis." American Journal of Preventive Medicine 44, no. 1 (January 2013): S80—S85. http://dx.doi.org/10.1016/j.amepre.2012.09.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Santos, Lorruan Alves dos, Alexandre Grangeiro, and Marcia Thereza Couto. "A Profilaxia Pré-Exposição ao HIV (PrEP) entre homens que fazem sexo com homens: comunicação, engajamento e redes sociais de pares." Ciência & Saúde Coletiva 27, no. 10 (October 2022): 3923–37. http://dx.doi.org/10.1590/1413-812320222710.06542022.

Full text

Abstract:

Resumo A Profilaxia Pré-Exposição ao HIV (PrEP) tem renovado o otimismo no controle da epidemia de HIV, não obstante seu contínuo crescimento entre os homens que fazem sexo com homens (HSH). A popularidade dos aplicativos de encontro afetivo-sexual e plataformas de mídias digitais na troca de informações e experiências sobre PrEP nas redes sociais de pares é reconhecida, embora sejam escassos estudos sobre contextos, motivações e alcance em termos da prevenção ao HIV. O artigo objetiva compreender a dinâmica das redes de pares virtuais e presenciais entre HSH para a decisão de usar PrEP, sua revelação e publicização. Estudo qualitativo com uso de entrevistas semiestruturadas com 48 usuários de PrEP de cinco cidades brasileiras. A maioria dos entrevistados compartilha informações e experiências sobre PrEP nas redes sociais de pares, contudo sua publicização revela tensões decorrentes da permanência de estigmas associados à homossexualidade e ao HIV. O protagonismo na revelação do uso da PrEP expressa engajamento em conquistar novos usuários. A relevância das redes sociais de pares no compartilhamento de experiências e informações sobre a PrEP tem potencial para a diversificação do público-alvo, ampliação e democratização da cobertura de PrEP no país.

APA, Harvard, Vancouver, ISO, and other styles

34

Joob, Beuy, and Viroj Wiwanitkit. "Pre-exposure and Post-exposure prophylaxis for dog bites." African Journal of Paediatric Surgery 14, no. 1 (2017): 18. http://dx.doi.org/10.4103/ajps.ajps_66_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ribeiro, Sofia, and Miguel Rocha. "Pre-Exposure Prophylaxis Counseling in a Community Sexual Health Clinic for Men Who Have Sex with Men in Lisbon, Portugal." Acta Médica Portuguesa 32, no. 6 (June 28, 2019): 441. http://dx.doi.org/10.20344/amp.11474.

Full text

Abstract:

Introduction: Pre-exposure prophylaxis is defined as the use of antiretroviral drugs to prevent HIV acquisition in uninfected individuals. Recognizing the increasing use of informal pre-exposure prophylaxis in Portugal, CheckpointLX, a community clinic targeted to men who have sex with men in Lisbon, Portugal, began offering counselling and follow-up services prior to formal introduction. This study aims to characterize pre-exposure prophylaxis users attending CheckpointLX before formal pre-exposure prophylaxis introduction in Portugal, and those who were referred to pre-exposure prophylaxis in the National Health Service following formal approval of pre-exposure prophylaxis.Material and Methods: Data was collected by peer counsellors between May 2015 and September 2018 and inserted in a database. Medical care followed the European AIDS Clinical Society recommendations for pre-exposure prophylaxis eligibility, initiation and follow-up. For formal pre-exposure prophylaxis, the General-Directorate for Health’s Pre-exposure Prophylaxis guidelines checklist was used.Results: Until the end of May 2018, CheckpointLX had a total of 90 appointments for wild pre-exposure prophylaxis, of which 64 (71%) were first time visits. As for the 380 service users referred to the National Health Service, most were Portuguese (n = 318, 84%), and the mean age was 31 (8.9) years old. Condomless sex in the last six months with partners of unknown HIV status was the most common eligibility criteria (n = 59, 83%).Discussion: Pre-exposure prophylaxis delivery should be complemented with effective information on the importance of immunization and education on safer practices of drug administration, in the scope of broader preventive sexual health care.Conclusion: Much remains to be done in Portugal to ensure that pre-exposure prophylaxis is available to those who need it the most. Offering pre-exposure prophylaxis at community clinics could be a first step.

APA, Harvard, Vancouver, ISO, and other styles

36

Kenison, Tiffany Cho, Brittan Badenhop, and Stella Safo. "Unlocking HIV Pre-Exposure Prophylaxis Delivery: Examining the Role of HIV Providers in Pre-Exposure Prophylaxis Care." AIDS Patient Care and STDs 34, no. 6 (June 1, 2020): 251–58. http://dx.doi.org/10.1089/apc.2019.0288.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

ÇINAR, Güle, and Serhat BİRENGEL. "Pre-exposure Prophylaxis Against Human Immunodeficiency Virus." Flora the Journal of Infectious Diseases and Clinical Microbiology 23, no. 1 (March 1, 2018): 1–7. http://dx.doi.org/10.5578/flora.66513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kessels, Jocelyn A., Sergio Recuenco, Ana Maria Navarro-Vela, Raffy Deray, Marco Vigilato, Hildegund Ertl, David Durrheim, et al. "Pre-exposure rabies prophylaxis: a systematic review." Bulletin of the World Health Organization 95, no. 3 (November 25, 2016): 210–19. http://dx.doi.org/10.2471/blt.16.173039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Mushtaq, Ammara, and Farooq Kazi. "Updates in pre-exposure prophylaxis for HIV." Lancet Infectious Diseases 22, no. 3 (March 2022): 320. http://dx.doi.org/10.1016/s1473-3099(22)00081-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Whelihan, Joseph Thomas, and Maureen Novak. "Pre-exposure Prophylaxis—Preventing HIV in Adolescents." JAMA Pediatrics 175, no. 12 (December 1, 2021): 1300. http://dx.doi.org/10.1001/jamapediatrics.2021.3274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bhatti, Osama, Darren So, Muhammad Abdullah Zahid, and Vincent J. Cornelisse. "Prescribing pre-exposure prophylaxis in general practice." Australian Journal of General Practice 50, no. 7 (July 1, 2021): 479–82. http://dx.doi.org/10.31128/ajgp-02-21-5829.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Shibata, Annemarie, Karl Khandalavala, Subhra Mandal, Rachel Pham, and Christopher J. Destache. "Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis." Journal of Nanotechnology and Materials Science 4, no. 2 (August 7, 2017): 53–61. http://dx.doi.org/10.15436/2377-1372.17.1583.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kecojevic, Aleksandar, Corey Basch, Charles Basch, and William Kernan. "Pre-Exposure Prophylaxis YouTube Videos: Content Evaluation." JMIR Public Health and Surveillance 4, no. 1 (February 16, 2018): e19. http://dx.doi.org/10.2196/publichealth.7733.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Haberer, Jessica E., David R. Bangsberg, Jared M. Baeten, Kathryn Curran, Florence Koechlin, K. Rivet Amico, Peter Anderson, et al. "Defining success with HIV pre-exposure prophylaxis." AIDS 29, no. 11 (July 2015): 1277–85. http://dx.doi.org/10.1097/qad.0000000000000647.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Streeck, Hendrik, Jens Verheyen, Julian Storim, Ulf Dittmer, Christoph Jochum, Jörg Timm, and Stefan Esser. "Pre-exposure prophylaxis failure with tenofovir disoproxil." AIDS 31, no. 1 (January 2017): 176–77. http://dx.doi.org/10.1097/qad.0000000000001280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kistan, Jesne, and David Serwadda. "Rethinking HIV pre-exposure prophylaxis prevention strategy." Lancet HIV 3, no. 4 (April 2016): e155-e157. http://dx.doi.org/10.1016/s2352-3018(16)00043-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Nandwani, Rak. "Pre-exposure prophylaxis is approved in Scotland." Lancet HIV 4, no. 6 (June 2017): e238-e239. http://dx.doi.org/10.1016/s2352-3018(17)30078-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

van de Wijgert, Janneke, and Sheena McCormack. "Vaginal dysbiosis and pre-exposure prophylaxis efficacy." Lancet HIV 4, no. 10 (October 2017): e427-e429. http://dx.doi.org/10.1016/s2352-3018(17)30130-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Stekler, Joanne D., Vanessa McMahan, Lark Ballinger, Luis Viquez, Fred Swanson, Jon Stockton, Beth Crutsinger-Perry, David Kern, and John D. Scott. "HIV Pre-exposure Prophylaxis Prescribing Through Telehealth." JAIDS Journal of Acquired Immune Deficiency Syndromes 77, no. 5 (April 2018): e40-e42. http://dx.doi.org/10.1097/qai.0000000000001621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

García-Lerma, J. Gerardo, Lynn Paxton, Peter H. Kilmarx, and Walid Heneine. "Oral pre-exposure prophylaxis for HIV prevention." Trends in Pharmacological Sciences 31, no. 2 (February 2010): 74–81. http://dx.doi.org/10.1016/j.tips.2009.10.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!